Amgen faces patent infringement claims on big-selling osteoporosis drug Evenity
May 3, 2023
Source: drugdu
125
In developing its osteoporosis drug Evenity more than a decade ago, it is alleged in court documents that Amgen discussed forming a potential partnership with a small company from Kansas.
Those discussions never amounted to a deal. Now, 11 years later, the Kansas company is suing Amgen for patent infringement.
The suit, filed in U.S. District Court in Massachusetts, claims Amgen's Evenity infringes on three of patents owned by OssiFi-Mab, including one that was granted last month. The first patent was awarded in 2012, the same year that Amgen and the Kansas company talked of a potential collaboration, according to the suit.
The patents refer to the “discovery of methods of increasing bone density via administration of a sclerostin antagonist together with an antiresorptive,” the complaint says. Evenity works in part by decreasing bone resorption by inhibiting the action of sclerostin, which helps regulate bone metabolism.
Amgen declined to comment on the suit.
Reference:https://news.bloomberglaw.com/ip-law/amgen-sued-for-patent-royalties-on-evenity-osteoporosis-drug
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Cornerstone Pharmaceuticals has reached a strategic cooperation on anti-PD-L1 monoclonal antibodies in the Middle East and Africa regions November 22, 2024
- Hand in hand with Merck and acquire shares from Zhongsheng Pharmaceutical! Lixin Pharmaceutical has become a dark horse in the development of new drugs, with a total pipeline BD transaction volume exceeding 28 billion yuan November 22, 2024
- Junshi Biotechnology introduces two cancer dual target fusion protein drugs November 22, 2024
- China Biopharmaceuticals announces signing equity investment and strategic cooperation agreement with Lixin Pharmaceutical November 22, 2024
- As the industry is going down, more and more pharmaceutical companies are seeking to “exit”? November 22, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
